IN MODERATE TO SEVERE PLAQUE PSORIASIS

PATHWAYS FOR PATIENTS TO START AND STAY ON TREMFYA^®

CLINICAL DECISION
TO START TREMFYA^®

Trial Dose (optional): If a trial is needed, prescriber may request a TREMFYA^® trial through either the So Simple Trial Program*

a Professional Sample. Trial program choice is at the prescriber’s discretion.

*The TREMFYA^® So Simple Trial Program provides patients their first dose of TREMFYA^® so they may determine with their provider if it is right for them. This trial program is open to patients who have commercial insurance, government coverage, or no insurance coverage. However, there is no guarantee of continuous accessibility after the program ends.

Ask your TREMFYA^® Sales Representative for additional information and details.

PRIOR AUTHORIZATION SUPPORT^† FOR TREMFYA^®

PROVIDERS CAN VISIT CoverMyMeds.com OR JanssenCarePathPortal.com

VIEW DETAILS

^†CoverMyMeds does not fill out any information that requires the medical judgment of the prescriber, and only the prescriber can determine whether to submit a prior authorization for a determination.

COVERAGE
DETERMINATION

FOR COMMERCIALLY INSURED PATIENTS

If Prior Authorization is approved:

Savings Program

Express Enrollment

VIEW DETAILS

If coverage determination is delayed >5 business days or denied:

VIEW DETAILS

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

PATHWAYS FOR PATIENTS TO START AND STAY ON TREMFYA^®

Ask your TREMFYA^® Sales Representative for additional information and details.

PROVIDERS CAN VISIT CoverMyMeds.com OR JanssenCarePathPortal.com

FOR COMMERCIALLY INSURED PATIENTS

If Prior Authorization is approved:

If coverage determination is delayed >5 business days or denied:

Janssen CarePath
Savings Program

Eligible patients pay

per injection. Maximum program benefit per calendar year shall apply.

We can help make it simple for you to help your patients

PATIENTS CAN GET TREMFYA^® AT NO COST UNTIL THEY RECEIVE INSURANCE COVERAGE APPROVAL

IMPORTANT SAFETY INFORMATION

INDICATIONS

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

PATHWAYS FOR PATIENTS TO START AND STAY ON TREMFYA®

Ask your TREMFYA® Sales Representative for additional information and details.

PROVIDERS CAN VISIT CoverMyMeds.com OR JanssenCarePathPortal.com

FOR COMMERCIALLY INSURED PATIENTS

If Prior Authorization is approved:

If coverage determination is delayed >5 business days or denied:

Janssen CarePathSavings Program

Eligible patients pay

per injection. Maximum program benefit per calendar year shall apply.

We can help make it simple for you to help your patients

PATIENTS CAN GET TREMFYA® AT NO COST UNTIL THEY RECEIVE INSURANCE COVERAGE APPROVAL

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

PATHWAYS FOR PATIENTS TO START AND STAY ON TREMFYA^®

Ask your TREMFYA^® Sales Representative for additional information and details.

Janssen CarePath
Savings Program

PATIENTS CAN GET TREMFYA^® AT NO COST UNTIL THEY RECEIVE INSURANCE COVERAGE APPROVAL